Welcome to our dedicated page for OKYO PHARMA news (Ticker: OKYO), a resource for investors and traders seeking the latest updates and insights on OKYO PHARMA stock.
OKYO Pharma Limited develops investigational ophthalmic therapies for neuropathic corneal pain and inflammatory eye diseases. The company’s lead candidate, urcosimod, formerly OK-101, is described as a lipid-conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, with development centered on ocular pain and inflammation.
Recurring company updates cover urcosimod clinical data, patient-reported outcomes from a completed Phase 2 study in neuropathic corneal pain, FDA IND and Fast Track status for the NCP program, scientific advisory and ophthalmology-conference presentations, ordinary-share ownership disclosures, and purchases of Nasdaq-listed ordinary shares by company insiders.
OKYO Pharma Limited is gearing up for a Q4 2022 IND filing for OK-101, targeting dry eye disease (DED) and supported by AmbioPharm. Following a successful pre-IND meeting with the FDA in Q1 2022, the Phase 2 trial is set to commence in Q1 2023, designed to expedite market entry. OK-101, a lipid-peptide analog, showcases potent anti-inflammatory properties in animal models, addressing a significant unmet need in the multibillion-dollar DED market.
OKYO Pharma Limited (NASDAQ: OKYO) announced its audited results for the year ending March 31, 2022. They reported a comprehensive loss of £3,976k and a cash balance of £2,056k. The company is advancing its lead candidate OK-101 for dry eye disease (DED) and plans to file an IND by Q4 2022, followed by a Phase 2 trial in early 2023. Preclinical studies showed significant efficacy for OK-101 in reducing corneal permeability and pain, with potential future evaluations for uveitis and allergic conjunctivitis.
On June 9, 2022, OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) announced that non-executive director Willy Simon acquired 361,195 ordinary shares at prices ranging from £0.02679 to £0.0284 each. This market purchase indicates Simon's confidence in the company's growth potential in the dry eye care sector. OKYO Pharma is focused on developing novel treatments for dry eye diseases and ocular pain, with its lead candidate, OK-101, demonstrating promising anti-inflammatory effects in preclinical studies.
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) announced that Panetta Partners Limited acquired 5,800,000 ordinary shares at £0.0625 each on May 19, 2022. This purchase increases Gabriele Cerrone's beneficial interest from 39.64% to 40.06%. However, dilution from a recent offering reduces his holdings to 39.08%. The company's focus on developing novel molecules for treating inflammatory dry eye diseases remains ongoing, highlighting its commitment to addressing significant medical needs in the eye care market.
OKYO Pharma announced the closing of its public offering of 625,000 American Depository Shares (ADSs) at $4.00 per share, totaling $2.5 million in gross proceeds. The funds will be utilized to advance the IND filing for OK-101 to treat dry eye disease (DED), support an initial Phase 2 clinical trial, and for general corporate purposes. ThinkEquity served as the sole book-running manager. This offering follows the effective registration statement filed with the SEC on May 16, 2022.
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) announced that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, purchased 25,000 American Depository Shares (ADS) at $3.8749 each on May 17, 2022. This transaction increased Cerrone's beneficial interest from 39.52% to 39.64%. However, with an upcoming offering closing on May 19, 2022, his stake will be diluted to 38.50%. The ADS represents 65 ordinary shares, and the transaction occurred on NASDAQ.
OKYO Pharma Limited has announced the pricing of its underwritten initial public offering (IPO) of American Depositary Shares (ADSs) on the Nasdaq Capital Market. The company will issue 625,000 ADSs at $4.00 each, raising approximately $2.5 million in gross proceeds. The offering is expected to close on May 19, 2022. Funds will be used for advancing clinical trials and general corporate needs. The total number of Ordinary Shares after the offering will reach 1,415,040,468.
OKYO Pharma Limited has announced a public offering of 625,000 American Depositary Shares (ADSs) at $4.00 each, expected to raise approximately $2,500,000. An additional 93,750 ADSs may be purchased by underwriters to cover over-allotments. The offering is set to close on May 19, 2022, pending customary conditions. Proceeds will fund the IND filing for OK-101 targeting Dry Eye Disease (DED) and support an initial Phase 2 clinical trial. The ADSs will begin trading on Nasdaq under the symbol ‘OKYO’ from May 17, 2022.